GRAY vs. CARA, IMRX, VYNE, EQ, LPCN, DARE, LSTA, RVPH, ENLV, and AKTX
Should you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include Cara Therapeutics (CARA), Immuneering (IMRX), VYNE Therapeutics (VYNE), Equillium (EQ), Lipocine (LPCN), Daré Bioscience (DARE), Lisata Therapeutics (LSTA), Reviva Pharmaceuticals (RVPH), Enlivex Therapeutics (ENLV), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical preparations" industry.
Graybug Vision (NASDAQ:GRAY) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.
49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are held by institutional investors. 7.9% of Graybug Vision shares are held by company insiders. Comparatively, 3.1% of Cara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cara Therapeutics received 651 more outperform votes than Graybug Vision when rated by MarketBeat users. Likewise, 74.19% of users gave Cara Therapeutics an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote.
Graybug Vision has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
Graybug Vision has a net margin of 0.00% compared to Cara Therapeutics' net margin of -723.49%. Graybug Vision's return on equity of -77.61% beat Cara Therapeutics' return on equity.
In the previous week, Cara Therapeutics had 1 more articles in the media than Graybug Vision. MarketBeat recorded 4 mentions for Cara Therapeutics and 3 mentions for Graybug Vision. Cara Therapeutics' average media sentiment score of 0.42 beat Graybug Vision's score of 0.33 indicating that Cara Therapeutics is being referred to more favorably in the news media.
Cara Therapeutics has a consensus price target of $3.93, suggesting a potential upside of 956.21%. Given Cara Therapeutics' higher possible upside, analysts plainly believe Cara Therapeutics is more favorable than Graybug Vision.
Graybug Vision has higher earnings, but lower revenue than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.
Summary
Cara Therapeutics beats Graybug Vision on 8 of the 15 factors compared between the two stocks.
Get Graybug Vision News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Graybug Vision Competitors List
Related Companies and Tools
